Boston Common Asset Management LLC cut its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 15.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 91,740 shares of the company's stock after selling 16,376 shares during the period. Boston Common Asset Management LLC's holdings in Novartis were worth $14,377,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. J.W. Cole Advisors Inc. increased its stake in shares of Novartis by 0.6% during the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company's stock worth $1,348,000 after purchasing an additional 64 shares in the last quarter. Roundview Capital LLC lifted its stake in Novartis by 2.5% in the 4th quarter. Roundview Capital LLC now owns 2,711 shares of the company's stock valued at $374,000 after buying an additional 66 shares in the last quarter. IMA Advisory Services Inc. boosted its holdings in Novartis by 10.9% in the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company's stock worth $98,000 after buying an additional 70 shares during the last quarter. Moody National Bank Trust Division increased its stake in Novartis by 4.2% during the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company's stock worth $282,000 after buying an additional 72 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC increased its stake in Novartis by 3.5% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company's stock worth $307,000 after buying an additional 75 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company's stock.
Analyst Ratings Changes
Several research firms have recently weighed in on NVS. Citigroup restated a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Novartis presently has a consensus rating of "Hold" and a consensus target price of $141.20.
Get Our Latest Stock Report on Novartis
Novartis Trading Down 0.3%
NVS opened at $151.85 on Friday. The firm has a market capitalization of $289.76 billion, a price-to-earnings ratio of 22.90, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The company's 50 day simple moving average is $153.68 and its two-hundred day simple moving average is $153.41. Novartis AG has a 1-year low of $120.78 and a 1-year high of $170.46. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67.
Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The business had revenue of $14.95 billion during the quarter. Analysts expect that Novartis AG will post 8.85 EPS for the current fiscal year.
Novartis Company Profile
(
Free Report)
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
